VOGX
Vogenx, Inc.CIK 0001903784 · SIC 2834 · Pharmaceutical Preparations
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (DPZ 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade VOGX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Vogenx prices $81.2M IPO at $13/share; clinical-stage biotech with material weaknesses and going-concern warning
7 material changes detected. Sign up free to read the summary.
Vogenx removes funding conditions from trial timelines in latest S-1/A
4 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Sep 17, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Statements of Operations (Unaudited)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses | ||||
| Research and development | 156,786 | 136,392 | 394,695 | 305,703 |
| General and administrative | 198,598 | 174,268 | 423,841 | 377,155 |
| Total operating expenses | 355,384 | 310,660 | 818,536 | 682,858 |
| Other income (expense) | ||||
| Change in fair value of warrant liability | 2,831 | 14,154 | 9,908 | 26,892 |
| Change in fair value of convertible promissory notes payable, related party | (31,900) | - | (51,400) | - |
| Interest income | 23 | 1,709 | 146 | 4,550 |
| Total other income (expense) | (29,046) | 15,863 | (41,346) | 31,442 |
| Net loss | (384,430) | (294,797) | (859,882) | (651,416) |
| Net loss per common share basic and diluted | (0.07) | (0.05) | (0.16) | (0.12) |
| Weighted average common shares outstanding basic and diluted | 5,451,873 | 5,451,873 | 5,451,873 | 5,451,873 |
Condensed Balance Sheets
| Description | June 30, 2026 (Unaudited) | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | 193,017 | 601,010 |
| Deferred offering costs | 1,204,631 | 63,363 |
| Prepaid expenses and other current assets | 11,380 | 16,797 |
| Total current assets | 1,409,028 | 681,170 |
| Total assets | 1,409,028 | 681,170 |
| Liabilities and stockholders’ deficit | ||
| Current liabilities | ||
| Accounts payable | 1,223,671 | 62,964 |
| Accrued expenses | 1,095,543 | 709,818 |
| Warrant liability | 1,415 | 11,323 |
| Convertible promissory notes payable, related party | 867,700 | 816,300 |
| Total current liabilities | 3,188,329 | 1,600,405 |
| Total liabilities | 3,188,329 | 1,600,405 |
| Commitments and contingencies | ||
| Stockholders’ deficit | ||
| Series A convertible preferred stock, $0.0001 par value; 15,000,000 shares authorized; 5,661,422 shares issued and outstanding as of June 30, 2026 and December 31, 2025 | 566 | 566 |
| Common shares, $0.0001 par value; 50,000,000 shares authorized; 5,263,158 shares issued and outstanding as of June 30, 2026 and December 31, 2025 | 526 | 526 |
| Additional paid-in capital | 9,921,159 | 9,921,343 |
| Accumulated deficit | (11,701,552) | (10,841,670) |
| Total stockholders’ deficit | (1,779,301) | (919,235) |
| Total liabilities and stockholders’ deficit | 1,409,028 | 681,170 |
Condensed Statements of Cash Flows (Unaudited)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | (859,882) | (651,416) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | (184) | 5,242 |
| Change in fair value of convertible promissory notes payable, related party | 51,400 | - |
| Change in fair value of warrant liability | (9,908) | (26,892) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 5,417 | (9,697) |
| Accounts payable | 104,313 | (39,259) |
| Accrued expenses | 385,725 | 149,375 |
| Net cash used in operating activities | (323,119) | (572,647) |
| Cash flows from financing activities | ||
| Payments related to offering costs | (84,874) | - |
| Net cash used in financing activities | (84,874) | - |
| Net decrease in cash and cash equivalents | (407,993) | (572,647) |
| Cash and cash equivalents, beginning of period | 601,010 | 962,923 |
| Cash and cash equivalents, end of period | 193,017 | 390,276 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Deferred offering costs (unpaid portion included in accounts payable) | (1,056,394) | - |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗